comparemela.com

Latest Breaking News On - Prnewswire neurosense therapeutics ltd - Page 8 : comparemela.com

NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomCompany phasePrnewswire neurosense therapeutics ltdDrug administrationNeurosense therapeutics ltdEuropean medicines agencyItalian medicines agencySense therapeuticsMassachusetts general hospitalNeuron derived exosomesOrphan drug designation

NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomCompany investigational new drugPrnewswire neurosense therapeutics ltdDrug administrationNeurosense therapeutics ltdEuropean unionEuropean medicines agencyNeurosense therapeuticsSense therapeuticsInvestigational new drugOrphan drug designationMassachusetts general hospitalNeuron derived exosomesHealth care amp hospitalsMedical pharmaceuticals

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesSan diegoUnited kingdomClearwater beachNiva russek blumShiran zimriFerenc tracikAmyotrophic lateral sclerosis consortiumNeurosense head of scientific programResearch ambassadorsInternational symposiumPrnewswire neurosense therapeutics ltdNeurosense therapeutics ltdHot topicSociety for neuroscience sfnNeals peace committee

NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomNedira salzman frenkelNiva russek blumPrnewswire neurosense therapeutics ltdNeurosense vp business developmentNeurosense therapeutics ltdSense therapeuticsPartnering conference

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomFerenc tracikEuropean medicines agencyPrnewswire neurosense therapeutics ltdDrug administrationNeurosense therapeutics ltdSense therapeuticsChief medical officerOrphan drug designation

vimarsana © 2020. All Rights Reserved.